[Dose-dependent decrease of the rate of restenosis of stents in peripheral vessels with reviparin]

Area of Science:

• Vascular Surgery
• Pharmacology
• Interventional Cardiology

Background:

• Restenosis after femoropopliteal artery stenting remains a clinical challenge.
• Low molecular weight heparin (LMWH) is used to prevent thrombotic complications.
• Optimizing LMWH dosage may improve outcomes after stenting.

Purpose of the Study:

• To evaluate the efficacy of reviparin, a LMWH, in reducing restenosis rates.
• To compare the effects of different reviparin dosages after Strecker stent implantation.
• To assess the safety and patency rates associated with reviparin treatment.

Main Methods:

• Prospective clinical trial involving 62 patients undergoing femoral popliteal artery stenting.
• Patients received either a low dose (1750 IU twice daily) or high dose (3500 IU twice daily) of reviparin.
• Follow-up included clinical assessment, ankle-brachial index, Doppler ultrasound, and digital subtraction angiography (DSA).

Main Results:

• The high-dose reviparin group showed significantly lower restenosis rates compared to the low-dose group (p < 0.005).
• Primary patency rates were 88% at one year and 80% at two years with high-dose reviparin.
• The complication rate was low, with only one moderate hematoma and one puncture aneurysm observed.

Conclusions:

• High-dose reviparin administration effectively lowers restenosis rates after femoropopliteal artery stenting.
• This dosage regimen offers superior primary patency compared to low-dose LMWH or unfractionated heparin.
• Reviparin is a safe and effective option for managing patients undergoing femoropopliteal stenting.